Skip to main content

Fierce Pharma Asia—Lilly's COVID-19 antibody results, Asahi Kasei deal; Takeda's EGFR lung cancer data




 Eli Lilly said its two-drug COVID-19 antibody cocktail could prevent hospitalization or death among high-risk patients. The Indianapolis pharma in-licensed a neuroinflammatory pain candidate from Asahi Kasei Pharma for $20 million upfront. Takeda's new tyrosine kinase inhibitor mobocertinib reported positive phase 1/2 results in non-small cell lung cancer with the rare EGFR exon 20 insertions. And more.

1. Lilly antibody combo slashed COVID-19 deaths, hospitalizations in high-risk patients

Eli Lilly said its COVID-19 antibody cocktail of bamlanivimab and etesevimab cut the risk of hospitalization or death among high-risk patients by 70% in a phase 3 study. Lilly got bamlanivimab from AbCellera and etesevimab from China’s Junshi Biosciences. However, to rain on Lilly’s parade, a Columbia University team found the combo couldn’t neutralize the highly transmissible B.1.351 variant of the coronavirus in the lab.

2. Lilly lands clinical-phase pain drug via deal with Asahi Kasei

Lilly paid Asahi Kasei Pharma $20 million upfront for rights to P2X7 receptor antagonist AK1780 in markets outside Japan and China. The drug holds promise in neuroinflammatory pain conditions and recently completed phase 1 studies. Along the way, the Japanese firm could receive up to $210 million in development and regulatory milestones and another $180 million tied to sales.

3. WCLC: Takeda's new kinase inhibitor curbs 78% of lung cancers with rare EGFR mutation

Takeda showed its tyrosine kinase inhibitor mobocertinib curbed tumor growth in 78% of 114 previously treated patients with metastatic non-small cell lung cancer with EGFR exon 20 insertions in a phase 1/2 trial. This tumor abnormality accounts for about 10% of all EGFR mutations. Currently, AstraZeneca’s Tagrisso and Genentech’s Tarceva are meant for other more prevalent types of EGFR mutations.

4. BeiGene, Novartis' PD-1 tislelizumab beats chemotherapy in esophageal cancer

BeiGene’s PD-1 inhibitor tislelizumab beat physician’s choice chemotherapy at helping previously treated esophageal cancer patients live longer. The phase 3 success marked the second global pivotal trial win for the drug, which Novartis just in-licensed in a deal worth up to $2.2 billion. A global phase 3 testing tislelizumab alongside chemotherapy in previously untreated patients could read out later this year.

5. WCLC: AstraZeneca, Daiichi Sankyo's Enhertu shows more phase 2 lung cancer promise

AstraZeneca and Daiichi Sankyo’s Enhertu spurred a response in 24.5% of heavily pretreated patients with HER2-overexpressing non-small cell lung cancer (NSCLC) in the phase 2 DESTINY-Lung01 study. Previously, the antibody-drug conjugate reported a 61.9% tumor shrinkage rate in the broader HER2-mutant NSCLC cases in the same trial. About 2% to 4% of NSCLC patients have HER2 mutations, and the over-expression population makes up one-third of those.

6. Sun Pharma goes for humor with a feather duster to the face in first Cequa DTC campaign for dry eyes

Sun Pharma is launching a multimedia DTC campaign for dry eye treatment Cequa. The ad, called “Battle Back,” draws a feather duster stuck to the face of a woman driving a car to get the message across about the discomfort of dry eyes. The lighthearted ad came after Sun conducted significant qualitative and quantitative market research to determine patients’ reactions.


https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-lilly-s-covid-antibody-results-asahi-kasei-deal-takeda-s-egfr-lung

Comments

Popular posts from this blog

Can We Make A Vaccine Against Smoking?

  This segment sounds good but we need to be careful here or we end up where we started in 2021 vaccines becoming political. 

Texas governor bans vaccine passports from being required in state ABC News

  Thats Right States like Texas and Florida got the Vaccine Passport Conspiracy from Del Bigtree.  https://abc7.com/politics/texas-governor-bans-vaccine-passport-requirement-in-state/10491161/ AUSTIN, Texas -- Gov. Greg Abbott issued an executive order Tuesday morning prohibiting state agencies or political subdivisions in Texas from creating a "vaccine passport" requirement. Conversation has grown around  vaccine passports recently as an option that can be used for travel or even eating out . They are typically described as an app with a code that verifies if someone has been vaccinated or recently tested negative for COVID-19. They're already in use in Israel, and in development in parts of Europe. But Abbott shut that down as an option in the Lone Star State with Executive Order No. GA - 35 also prohibiting "organizations receiving public funds from requiring consumers to provide documentation of vaccine status in order to receive any service or enter any place....

Anti-Vax Conspiracies strike back in the USA July 2021 Original Article

 Thumbnail credit by Jeff Holiday Production In the past few weeks the anti-vax lobby has ratcheted up the ante on their lobbying efforts. The event that kicked off this new wave of anti-vax scares was the "Knock on the Door rants" according to the Washington Post on a July 9th article they cited  rants by Marjorie Taylor Greene and Laurent Boebert in a political rally that sparked the scare. "Rep. Marjorie Taylor Greene (R-Ga.) got the ball rolling Tuesday by comparing the effort to “ medical brown shirts showing up at their door ordering vaccinations .” Not to be outdone, Rep. Lauren Boebert (R-Colo.) took to Twitter the next day to offer her own Nazi comparison, labeling the door-knockers “ needle Nazis .” If anyone should know the folly of such metaphors, it would seem to be Greene, who just three weeks prior conceded in an apology after another wayward Nazi/coronavirus comment that “ there is no comparison to the Holocaust .” And it’s worth emphasizing that there is...